# IDeate-Lung03 (NCT06362252)

> A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06362252
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Extensive Stage-small Cell Lung Cancer
- Interventions: Ifinatamab deruxtecan; Atezolizumab; Carboplatin
- Enrollment: 123
- Primary outcome: Number of Participants Reporting Dose-limiting Toxicities Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A)
- Primary outcome: Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ideate-lung03-nct06362252